Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1
试验速览
- 阶段
- 不适用
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Relapse free survival
研究概览
简要总结
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival. However, there are still considerable number of patients experience relapse even after adjuvant chemotherapy. In an attempt to select patients who really benefit the postoperative adjuvant chemotherapy, we have identified potential biomarkers (NF-kappaB/JNK) from cell line panel screening followed by immunohistochemical validation. In the present study, we further validate the significance of the biomarkers in a larger set of clinical samples to see if chemotherapeutic response can be determined immediately after surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed gastric cancer.
- •Operated before November
- •Stage Ib/II(except for T1, T3N0)/III.
- •Received postoperative (R0) adjuvant chemotherapy (S-1).
- •Not received postoperative (R0) adjuvant chemotherapy (surgery alone).
- •Signed informed consent to provide paraffin embedded tissue of removed specimens.
排除标准
- •With advanced neoplastic lesions other than gastric cancer.
- •Paraffin embedded tissue is not available.
- •Unknown S-1 treatment condition.
结局指标
主要结局
Relapse free survival
时间窗: 3 years
次要结局
未报告次要终点
研究者
Satoshi Nishizuka
Assistant Professor
Iwate Medical University